Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells.

Melguizo C, Prados J, Marchal JA, Vélez C, Carrillo E, Boulaiz H, Sánchez-Montesinos I, Madeddu R, Aránega A.

Neoplasma. 2003;50(2):91-6.

PMID:
12740641
2.

Multidrug resistance and rhabdomyosarcoma (Review).

Melguizo C, Prados J, Rama AR, Ortiz R, Álvarez PJ, Fernández JE, Aranega A.

Oncol Rep. 2011 Oct;26(4):755-61. doi: 10.3892/or.2011.1347. Epub 2011 Jun 15. Review.

PMID:
21687952
3.

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.

Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F.

Cancer Immunol Immunother. 2008 Nov;57(11):1727-33. doi: 10.1007/s00262-008-0532-3. Epub 2008 May 20. Review.

PMID:
18491093
4.

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.

Mendez R, Aptsiauri N, Del Campo A, Maleno I, Cabrera T, Ruiz-Cabello F, Garrido F, Garcia-Lora A.

Cancer Immunol Immunother. 2009 Sep;58(9):1507-15. doi: 10.1007/s00262-009-0701-z. Epub 2009 Apr 2. Review.

PMID:
19340423
5.

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.

Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F.

Cancer Immunol Immunother. 2004 Oct;53(10):904-10. Epub 2004 Apr 7. Review.

PMID:
15069585
6.

The molecular biology of childhood rhabdomyosarcoma.

Parham DM.

Semin Diagn Pathol. 1994 Feb;11(1):39-46. Review.

PMID:
7911248
7.

Targeting the fetal acetylcholine receptor in rhabdomyosarcoma.

Simon-Keller K, Barth S, Vincent A, Marx A.

Expert Opin Ther Targets. 2013 Feb;17(2):127-38. doi: 10.1517/14728222.2013.734500. Epub 2012 Dec 11. Review.

PMID:
23231343
8.

Engaging Cell Death Pathways for the Treatment of Rhabdomyosarcoma.

Dobson CC, Langlois S, Grynspan D, Cowan KN, Holcik M.

Crit Rev Oncog. 2016;21(3-4):221-239. Review.

PMID:
27915973

Supplemental Content

Support Center